African Bundibugyo ebolavirus vaccine candidate to be advanced to clinical trials

Trial StartBundibugyo ebolavirus vaccine candidatePositive

AI Analysis

Summary

CEPI has backed Minapharm Group's Bundibugyo ebolavirus vaccine candidate, which is based on ProBioGen's MVA-CR19 platform and is advancing to clinical trials. The vaccine targets Bundibugyo ebolavirus and represents an African-led biopharmaceutical development effort.

Clinical Trial Data

Phase

Outcome Details

vaccine candidate advancing to clinical trials

Importance:6/10

Sentiment:

0.60

vaccineebolavirusclinical_trialsAfricainfectious_diseaseCEPIMVA platform

Read the original article

Published by PR Newswire Pharma on August 27, 2026 11:27 AM

Read Original